---
title: "Jefferies Remains a Buy on Enliven Therapeutics (ELVN)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289798909.md"
description: "In a report released today, from Jefferies maintained a Buy rating on Enliven Therapeutics, with a price target of $59.00.Claim 55% Off TipRanks Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter. Currently, the analyst consensus on Enliven Therapeutics is a Strong Buy with an average price target of $59.63."
datetime: "2026-06-15T14:20:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289798909.md)
  - [en](https://longbridge.com/en/news/289798909.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289798909.md)
generator: "portal-rs"
---

# Jefferies Remains a Buy on Enliven Therapeutics (ELVN)

In a report released today, from Jefferies maintained a Buy rating on Enliven Therapeutics, with a price target of $59.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

Currently, the analyst consensus on Enliven Therapeutics is a Strong Buy with an average price target of $59.63.

### Related Stocks

- [ELVN.US](https://longbridge.com/en/quote/ELVN.US.md)
- [JEF.US](https://longbridge.com/en/quote/JEF.US.md)

## Related News & Research

- [Handelsbanken Fonder AB Buys New Shares in Enliven Therapeutics, Inc. $ELVN](https://longbridge.com/en/news/296460096.md)
- [Mizuho Securities Keeps Their Buy Rating on Enliven Therapeutics (ELVN)](https://longbridge.com/en/news/296131282.md)
- [Jefferies Reaffirms Their Buy Rating on NKT A/S (0MGC)](https://longbridge.com/en/news/297651129.md)
- [AcuCort notifies availability of August 2026 newsletter press release](https://longbridge.com/en/news/297505730.md)
- [Rein Therapeutics presents late-breaking ERS poster on inhaled LTI-03 idiopathic pulmonary fibrosis dose-escalation trial](https://longbridge.com/en/news/298034930.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**